Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of “Hold” by Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has received a consensus rating of “Hold” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $62.1667.

Several equities analysts recently weighed in on the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 23rd. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Finally, Zacks Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 50,000 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $50.28, for a total value of $2,514,000.00. Following the sale, the vice president directly owned 17,044 shares in the company, valued at approximately $856,972.32. The trade was a 74.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frederick M. Hudson sold 5,369 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $50.61, for a total value of $271,725.09. Following the completion of the sale, the director owned 60,413 shares in the company, valued at $3,057,501.93. This represents a 8.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 97,619 shares of company stock valued at $4,908,275. 8.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Hantz Financial Services Inc. lifted its position in shares of Supernus Pharmaceuticals by 81.7% in the third quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 281 shares in the last quarter. Rockefeller Capital Management L.P. increased its stake in Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after acquiring an additional 660 shares during the last quarter. Torren Management LLC bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth approximately $49,000. EverSource Wealth Advisors LLC bought a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $51,000. Finally, Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 268 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $45.66 on Wednesday. The company has a market capitalization of $2.65 billion, a PE ratio of -89.53, a price-to-earnings-growth ratio of 0.95 and a beta of 0.55. The business’s fifty day moving average is $49.03 and its 200 day moving average is $49.56. Supernus Pharmaceuticals has a fifty-two week low of $30.83 and a fifty-two week high of $59.68.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.